Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
61. |
ECCT/24/07/05 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Dr Bernhards Ogutu Site(s) in Kenya 1. HOMA BAY COUNTY TEACHING AND REFERRAL HOSPITAL SITE (Homa Bay county) |
20-08-2024 |
View |
62. |
ECCT/24/02/09 | pionERA This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy. |
Principal Investigator(s) 1. Dr Sitna Ali Site(s) in Kenya University of Nairobi -Institute of Tropical and Infectious Diseases |
04-08-2024 |
View |
63. |
ECCT/24/06/07 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Charity Wambui Kanyoro Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) |
28-07-2024 |
View |
64. |
ECCT/24/02/06 | INAVO122 A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Inavolisib in combination with Phesgo versus placebo in combination with Phesgo as maintenance therapy after first line induction therapy in participants with PIK3CAâ€mutated HER2â€positive locally advanced or metastatic breast cancer |
Principal Investigator(s) 1. Dr Sitna Ali Site(s) in Kenya University of Nairobi -Institute of Tropical and Infectious Diseases |
03-07-2024 |
View |
65. |
ECCT/24/04/02 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL |
Principal Investigator(s) 1. Dr Fredrick Kipyego Sawe Site(s) in Kenya 1. Walter Reed Army Institute of Research -Kericho Site (Kericho county) |
03-07-2024 |
View |
66. |
ECCT/24/06/01 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Raymond Scott McClelland Site(s) in Kenya 1. Pwani Research Centre (Mombasa county) |
02-07-2024 |
View |
67. |
ECCT/24/03/04 | MK8591A-053 Trial A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants |
Principal Investigator(s) 1. Elizabeth Anne Bukusi 2. Nelly Rwamba Mugo Site(s) in Kenya 1. Site 8650, KEMRI-CMR-RCTP, Kisumu (Kisumu county) 2. Site 8651, KEMRI-CCR-PHRD, Thika (Kiambu county) 3. Site 8652, KEMRI-CCR, NAIROBI (Nairobi City county) |
19-06-2024 |
View |
68. |
ECCT/24/02/10 | IMBrave A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA |
Principal Investigator(s) 1. Dr. Pauline Njoki Njiraini Site(s) in Kenya University of Nairobi -Institute of Tropical and Infectious Diseases |
09-06-2024 |
View |
69. |
ECCT/24/04/01 | B/F/TAF to DTG/3TC Switch Stud Efficacy, Safety and Tolerability of Switching to DTG/3TC Single Tablet Regimen from B/F/TAF in Older Persons Living with HIV in Kenya |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) 2. Kenyatta National Hospital (Nairobi City county) |
02-06-2024 |
View |
70. |
ECCT/24/05/03 | SIBP-MMR-02 A Phase III, Multi-Center, Randomized, Observer-Blind, Active Controlled Non-Inferiority Study to Evaluate the Immunogenicity and Safety of Shanghai Institute of Biological Products Co., Ltd.’s Measles, Mumps and Rubella (MMR) Vaccine Compared to a Licensed and WHO Prequalified GSK MMR Vaccine in Healthy African Children, 9- 11 Months of Age |
Principal Investigator(s) 1. Dr Walter Otieno 2. Dr. Diana Odhiambo Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. Victoria Biomedical Research Institute (Kisumu county) |
27-05-2024 |
View |